NCT06570824Recruiting
rTMS as an Intervention for Levodopa-induced Dyskinesia
Network Based Repetitive Transcranial Magnetic Stimulation (rTMS) as an Intervention for Levodopa-induced Dyskinesia (LID) in Parkinson's Disease (PD)
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- First submitted
- 3 May 2024
- Start date
- 22 Aug 2024
- Primary completion date
- 1 May 2027
- Lead sponsor
- Danish Research Centre for Magnetic Resonance
- Diseases
- Parkinson disease
- NCT number
- NCT06570824
What you commit to
- Study type: Interventional
- Planned participants: 68
- From 22 Aug 2024 to the primary completion date, 1 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin).
Other illness
- Psychiatric disorders.
- History of neurological disease other than Parkinson's disease.
- History of epilepsy/conditions associated with increased risk to seizure-induction through TMS.
- Close relatives suffering from epilepsy/conditions associated with increased risk to seizure-induction through TMS.
Age
- Female participants of childbearing age must not be pregnant and that they must use contraception during the trial.
Other
- Regular usage of benzodiazepines and opioids (more than once per week).
- Contraindications for MRI scan
- Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study.
Who the study is looking for
- Clinically established or probable PD
- Clinical Diagnostic Criteria for Parkinson's Disease
- Peak-of-dose levodopa-induced dyskinesia.
- Stable antiparkinsonian medicine for at least four weeks.
- Signed informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| DRCMR Coordinator of this site? Confirm its status | Hvidovre | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.